Glofitamab,Obinutuzumab,Tocilizumab
roche
['2000', 'obinu', 'glofitamab']
glofitamab monotherapy r/r mcl
phillips et al. - 37 pts, med age 72, med prio 3
- orr 84% / cr 73%
- durability of cr seen even when therapy stopped
- 4 covid deaths
- crs seen, less with 2g obinutuz prior to dosing
- ph3 trial planned
very impressive data. 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.